DOI:
10.1055/s-00035024
Thrombosis and Haemostasis
LinksClose Window
References
Advani RH, Buggy JJ, Sharman JP. , et al.
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
J Clin Oncol 2013;
31 (01) 88-94
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.